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Background: Piperaquine, 1,3-bis-[4-(7-chloroquinolyl-4)-piperazinyl-1]-propane, is an anti-malarial compound
belonging to the 4-aminoquinolines, which has received renewed interest in treatment of drug resistant falciparum
malaria in artemisinin-based combination therapy with dihydroartemisinin. The impurity profile of this drug product
is paid an ever-increasing attention. However, there were few published studies of the complete characterization of
related products or impurities in piperaquine phosphate bulk and forced degradation samples.
Methods: The impurities in piperaquine phosphate bulk drug substance were detected by a newly developed
gradient phase HPLC method and identified by TOF-MS and ESI-MS. The structures of impurities were confirmed by
NMR. Forced degradation studies were also performed for the stability of piperaquine phosphate bulk drug samples
and the specificity of the newly developed HPLC method. In silico toxicological predictions for these piperaquine
phosphate related impurities were made by Toxtree® and Derek®.
Results: Twelve impurities (imp-1–12) were detected and identified, of which eight impurities (imp-1, 2, 4, 6–10)
were first proposed as new related substances. Based on TOF-MS/ESI-MS and NMR analysis, the structures of imp-2,
6 and 12 were characterized by their synthesis and preparation. The possible mechanisms for the formation of
impurities were also discussed. These piperaquine phosphate related impurities were predicted to have a toxicity
risk by Toxtree® and Derek®.
Conclusions: From forced degradation and bulk samples of piperaquine phosphate, twelve compounds were
detected and identified to be piperaquine phosphate related impurities. Two of the new piperaquine phosphate
related substances, imp-2 and imp-6, were identified and characterized as 4-hydroxy-7-chloro-quinoline and a
piperaquine oxygenate with a piperazine ring of nitrogen oxide in bulk drug and oxidation sample, respectively.
The MS data of imp-1, 2, 4, 6–10 were first reported. The in-silico toxicological prediction showed a toxicity risk for
piperaquine related impurities by Toxtree® and Derek®.
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Malaria, caused by the mosquito-borne protozoan para-
site Plasmodium falciparum, is one of the major global
public health challenges with an estimated 219 million
clinical cases and 655,000 in 2010, mainly in children
aged less than five years old from sub-Saharan Africa [1,2].
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unless otherwise stated.propane, is an anti-malarial compound belonging to the
4-aminoquinolines, which was first synthesized as com-
pound 13228 RP by Rhone Poulenc in France in the
1950s. Piperaquine was rediscovered by Shanghai Re-
search Institute of Pharmaceutical Industry in the 1960s
and in 1970s, and rapidly replaced chloroquine as first-
line monotherapy in southern China [3], until resistance
emerged in the 1980s.
Recently piperaquine has received renewed interest in
treatment of drug resistant falciparum malaria, as it has
proved to be a suitable partner drug in artemisinin-based. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Yan et al. Malaria Journal 2014, 13:401 Page 2 of 12
http://www.malariajournal.com/content/13/1/401combination therapy (ACT) to improve anti-malarial ef-
fectiveness and to keep the selection of drug-resistant
parasites to minimum [4]. Meanwhile, it is now com-
mercially available in fixed combination products,
mostly with dihydroartemisinin, which are proved to
be highly efficacious for treatment of uncomplicated
falciparum malaria [5,6]. The anti-malarial therapeutic
efficacy studies conducted in Cambodia India and
Vietnam, showed that for Plasmodium vivax and P. fal-
ciparum infection the therapeutic efficacy of the treat-
ment of dihydroartemisinin-piperaquine remained high
(100%) as an appropriate new first-line treatment [6-8].
In China, the piperaquine tablets were recommended
at the dose of 600 mg monthly to prevent malaria. In
the toxicological and clinic research, the most common
adverse effects of piperaquine are dizziness, headache
and gastrointestinal symptoms (nausea, vomiting, diar-
rhoea and abdominal pain) with less frequent side
effects including urticaria, elevated serum alanine ami-
notransferase (ALT), low serum glucose, prolonged
electrocardiographic QT interval and decreased white
cell count [9-11]. An evaluation of piperaquine for
reproduction did not show any genotoxic or clasto-
genic potential. No evidence of adverse effects on preg-
nancy in humans and animals has been observed
[12,13]. The piperaquine combination exerted a signifi-
cant treatment and post-treatment prophylactic effects,
indicating that piperaquine is a new partner drug of
ACT displaying high efficacy and safety in the treat-
ment of malaria.
The quality of a drug product is related not only with
the contents of the active drug substances, but also with
its impurities. Though there is an ever-increasing atten-
tion on impurity profile, just Chinese Pharmacopeia has
already established specification limits for the total re-
lated impurities of piperaquine phosphate by HPLC-UV
method [14]. Zhang et al. [15] developed an LC method
for the analysis of piperaquine phosphate and related
substances with the impurities limit of 0.21% - 0.39%
under photo degradation condition. Now, it is mandatory
to identify and characterize the impurities in the pharma-
ceutical product, if present above the accepted limits of
0.1% [16]. Dongre et al. [17] detected and identified
only four impurities, such as 7-chloro-4-piperazinyl
quinoline, 1-chloro-3-(7-chloro-4-quinolyl-4-piperazinyl)
propane, 1-(1-5-chloro-4-quinolyl-4-piperazinyl)-3-(1-7-
chloro-4-quinolyl-4-piperazinyl) propane and 1,4-bis-(4,7-
dichloroquinoline) piperazine in piperaquine phosphate
bulk drug substance by gradient reverse phase high per-
formance liquid chromatographic (HPLC) and LC/MS/MS
methods. The structures of three impurities were synthe-
sized and confirmed by NMR and IR. Although these
studies based on HPLC, LC-MS/MS and spectroscopic
methods were reported in the literature for the qualityand quantitative analysis of piperaquine phosphate and its
impurities [14,15,17], there is few published studies of the
complete characterization of related products or impur-
ities in piperaquine phosphate as active pharmaceutical
ingredient.
In this study, twelve potential impurities were de-
tected, including new degradants, in piperaquine phos-
phate bulk sample using a newly developed gradient
reversed phase HPLC methods. A comprehensive study
was undertaken for the identification of these impurities
by LC-TOF/MS and ESI-MS followed by their synthesis
and further characterization by NMR. The in silico toxi-
cological evaluation of these impurities was exerted by
Toxtree® and Derek®.Methods
Samples and chemicals
The reference standards of piperaquine phosphate (pur-
ity > 99.0%), piperaquine phosphate bulk samples, 4-
hydroxy-7-chloro-quinoline (imp-2) (purity > 99.0%) and
1, 4-bis-(4, 7-dichloroquinoline) piperazine (imp-12) (pur-
ity > 99.0%) were kindly provided by Chongqing Southwest
No.2 Pharmaceutical Factory Co., LTD. 1, 3-bis [1, 4-(4,7-
dichloroquinoline) piperazin] propane nitrogen oxides
(imp-6) (purity > 98.0%) was prepared by HPLC in our la-
boratory from piperaquine phosphate forced degradation
samples. Acetonitrile of HPLC grade was used for the
analytical HPLC analysis, and purchased from Merk,
Darmstadt, Germany. Deionized water (18 MΩ cm) was
prepared with a Millipore Milli Q-Plus purification system
(Millipore Corp., MA, USA). Ammonium acetate and
ammonia water were of analytical reagent grade and pur-
chased from Sigma-Aldrich (St Louis, USA). Other re-
agents were analytical reagent grade and purchased from
Nanjing Chemical Co. (Nanjing, China). The NMR solvent
of dimethyl sulphoxide-d6 and tridecafluoroheptanoic
acid-d were purchased from Merk, Darmstadt, Germany.Chramatographic conditions
The HPLC-PDA chromatographic system consisting of a
Hitachi Chromaster separation module and a Hitachi
Chromaster photodiode array detector (Hitachi, Tokyo,
Japan) was used for analytical and preparative separa-
tions with Empower 3.0 software (Milford, MA, USA).
HPLC separation was performed on a Phecda C18 ana-
lytical column (250 mm × 4.6 mm, 5 μm) at temperature
of 30°C. The detection wavelength was set at 317 nm.
The gradient elution at the flow rate of 1.0 mL/min was
employed with acetonitrile as mobile phase A and 0.1%
ammonium acetate solution (pH adjusted to 7.0 by using
ammonia water) as mobile phase B, with the gradient
programme of time (min)/% A: 0/40, 5/40, 54/100, 54.1/
40, 60/40. The sample injection volume was 20 μL.
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Accurate mass measurements were performed on an
Agilent 6224 accurate-mass time-of-flight (TOF) mass
spectrometer with qualitative Analysis B.04.00 software
(All Agilent Technologies, Santa Clara, CA, USA). The
operating parameters in the positive ion detection mode
were as follows: drying gas (N2) flow rate, 10.0 L/min;
sheath gas temperature, 350°C; capillary, +4000 V; frag-
mentor, 135 V; skimmer,; collision energy,; and mass
range, 100–1500 Da. The ESI-MS/MS spectra was carried
out by Thermo-Finnigan TSQ Quantum Ultra tandem
mass spectrometer equipped equiped with an electrospray
ionization source (ESI), and Xcalibur 1.4 software was
used for data acquisition and processing (All Thermo-
Finnigan, San Jose, CA, USA). The mass spectra of ESI-
MS/MS were recorded in the same ion detection mode to
analysis the fragment ions of the related substances. The
spray voltage was set at 5000 V. The heated capillary
temperature was 350°C. The sheath gas and the auxiliary
gas were set at 45 and 10 psi, respectively. The fragment
ions were produced by collision-induced dissociation of
the selected precursor ions with the collision energy of
35 eV. In the LC-MS/MS measurements chromatographic
conditions described in the section of “Chromatographic
conditions” were used.
1H and 13C NMR spectroscopy
The 1H, 13C NMR spectra of the impurities was per-
formed on Bruker AVANCE DRX-500 spectrometer using
dimethyl sulphoxide-d6 as solvent and tetramethylsilane
(TMS) as internal standard.
Sample preparation
Preparation of forced degradation samples
Forced degradation studies can identify the degradation
products, establish the degradation pathways and find
the intrinsic stability of the molecule. The preparation of
all forced degradation samples were conducted by stres-
sing with acid (0.1 M HCl, 60°C, 30 min), alkaline
(0.1 M NaOH, 60°C, 30 min), hydrolysis and oxidation
(30% H2O2, room temperature, 30 min) and photo (UV
light and cool white fluorescent, 10 days) according to
option 2 of Q1B in ICH guidelines. The degraded sam-
ples were neutralized (for acidic and basic hydrolysed)
and diluted to final concentration of 800 μg/mL before
the assay of the degradation impurities.
Enrichment of impurity-6 in oxidation samples
The isolation and enrichment of imp-6 was performed on
a Shimadzu LC-2010 HT Liquid Chromatograph equipped
with a SPD-10AVP UV–vis detector (Shimadzu Corp.,
Kyoto, Japan). The Chromatographic conditions were per-
formed according to the section of “Chromatographic
conditions”. The test solution of oxidation samples (30%H2O2, room temperature, 12 h) was prepared at the
final concentration of 300 μg/mL. The imp-6 solution
was repeatedly collected at the retention time region
of 5.8-6.3 min, before evaporated to dryness under
high vaccum. The residue of imp-6 was obtained with
the purity above 98% based on HPLC analysis by area
normalization method.
In silico toxicological predictions
The structure-activity relationships ((Q)SAR), based on
the concept that chemical structure determines the bio-
logical activity of a molecule, are employed as scientific-
ally credible tools for predicting the acute toxicity of
chemicals relevant to public and animal health [18]. Re-
cently, these (Q)SAR programmes will play an important
role in future chemical policies, such as in the European
Union and the Netherlands, to reduce animal testing
and costs and to speed up the number of risk assess-
ments for hazardous chemicals. To evaluate the toxico-
logical characters of piperaquine related impurities in
silico, Toxtree® (v.1.60, Ideaconsult Ltd., Sofia, Bulgaria)
and Derek® (Nexus v3.0.1, Lhasa Limited, Leeds, UK)
were selected from different two sources of toxicity pre-
dictions [19,20]. Toxtree® is a full-featured and flexible
user-friendly open source application, which is able to
estimate toxic hazard by applying a decision tree ap-
proach and making (Q)SAR-based predictions for a
number of toxicological endpoints by different modules.
Three Toxtree® modules, such as Cramer rules with ex-
tension, Bengni/Bossa rulebase for mutagenicity and
carcinogenicity and structure alerts for the in vivo mi-
cronucleus assay in rodents, were used to generate haz-
ard estimations. Derek® for windows, a knowledge-based
expert system, predicts the toxicity of a compound from
its chemical structural alerts, rules and examples, which
describes relationship between a structural feature (toxi-
cophore) and its associated toxicity. A broad range of
toxicological endpoints are covered, including carcino-
genicity, genotoxicity, hepatotoxicity, HERG channel in-
hibition, reproductive toxicity and skin sensitization.
Results and discussion
Detection of impurities by HPLC-UV/DAD
The main aim of this study was to develop a selective
and sensitive method for analysis of piperaquine and
its related substances originated from the synthesis and
forced degradation. According to the reported methods
for the analysis of piperaquine [14,15,17], different types
of commercial C18 columns were tested for their select-
ivity toward the impurities and piperaquine. Finally, a
Phecda-C18 (250 mm× 4.6 mm, 5 μm) column was se-
lected. A volatile mobile phase was prerequisite for the
analysis of LC-MS. However, in most of the previous
method [14,15], the mobile phases contained non-volatile
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Although Dongre et al. [17] reported the analysis method
of volatile mobile phases, it showed the poor selectivity of
twelve impurities. Therefore, in our study, several mobile
phases consisting of different volatile buffers and organic
modifiers were tried with various gradient elution. The
solution of 0.1% ammonium acetate with pH of 7.0 was
more suitable than 0.01 M ammonium acetate or 0.2% for-
mic acid for baseline separation and symmetrical peaks, in
combination with acetonitrile as organic modifier (detailed
in Additional file 1). Optimized chromatographic condi-
tions were described in the section of “Chromatographic
conditions” and the typical chromatogram of a bulk sam-
ple was shown in Figure 1 (the typical chromatograms of
the samples from other API suppliers shown in Additional
file 2). The peak of piperaquine was completely separated
from all of twelve impurities in 60 minutes.
Forced degradation experiment was performed by
exposing piperaquine phosphate bulk to diverse stress
conditions for different periods. Degradation was not ob-
served in piperaquine forced samples subjected to photo
and acid. Significant degradation of the drug substance
and product was detected under basic and oxidative
forced conditions, leading to the formation of imp-6–10.
Peak purity test results derived from DAD detector, con-
firmed that the piperaquine peak and all of the impurity
peaks (imp-1–12) were homogeneous and pure in all of
the forced and bulk samples.
Structure elucidation of related impurities by
HPLC-ESI-MS/TOF-MS
All the MS and MSn spectrum of piperaquine and re-
lated impurities were obtained by the method described
in the section of “TOF-MS and ESI-MS conditions”.3 . 5 3
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Figure 1 UV chromatogram of piperaquine crude sample. The imp-1, 2
were the by-product in the synthetic reaction of piperaquine phosphate (P
imp-9 (9) was the degradation product of piperaquine phosphate.Mass spectra were recorded in positive ion mode (the
mass spectra of piperaquine and related impurities
shown in Additional files 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,
14 and 15). In order to understand the mass spectral
behaviour of related impurities, a detailed study of the
fragmentation pattern of the main drug component
was carried on. The accurate pseudomolecular ion peak
[M +H]+ of piperaquine, measured by Q-TOF instrument
was 535.2142 Da, in agreement with the reported data
(C29H32Cl2N6, MW = 534.2065) [17]. In the MS
n
spectrum, piperaquine produced fragmentation ion at
m/z 288 by the loss of 4-(7-chloro- quinoline-4-yl)
piperazine. The ion peaks at m/z 260 (−28 Da), 205
(−83 Da) and 217 (−71 Da) can be attributed to the loss
of -C2H5 group and the rearrangement of ring-opening,
respectively. The minor ion at 164 was generated by the
loss of -C2H5 group from the ion at m/z 205. The
additional fragment ion at 164 yielded low abundant
ion at 217, by the loss of four-numbered ring group.
The main fragmentation pattern was in agreement with
the literature data [17], and the probable fragmentation
pathway of piperaquine was shown in Figures 2, 3 and 4.
The TOF-MS and ESI-MS data and proposed chem-
ical structure of related impurities in bulk drug and forced
degradation samples were shown in Figure 5.
The imp-1 and the imp-2 (Figure 2), with accurate
positive ions at m/z 180.0208 and 180.0207, had the
same molecular formula for pseudomolecular ion (C9H7
ClNO+). In the MSn spectrum of imp-2, the main frag-
ment ions at 145, 117, 111 and 89 were attributed to
the structure of 7-chloro-quinoline. According to the
synthetic route of piperaquine and the literature, the
probable structure of imp-2 could be 4-hydroxy-7-
chloro-quinoline. The pseudomolecular ion of imp-1 atP
.0 7
3 0 . 9 8 3 5 . 5 2
0.00 35.00 40.00 45.00 50.00 55.00 60.0
12
, 4 (1, 2, 4) were the starting material. The imp-3, 5, 11, 12 (3, 5, 11, 12)
). The imp-6, 7, 8, 10 (6, 7, 8, 10) were the oxidation products and the
Figure 2 Probable fragmentation pathways of imp-1, 2 and 4.
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(−HCl). Further fragmentation of the ion at m/z 144
yielded an ion at m/z 116 by the loss of -CO group,
which indicated that a hydroxyl group substituted at a
different position of imp-2. Thus, the proposed struc-
ture of imp-1 could be 5-hydroxy-7 -chloro-quinoline.
The imp-4 (Figure 2) with the accurate protonated ion
at m/z 179.0369, yielded the ion at 144 with the same
ion of the imp-1 at 162, by the loss of -NH3 group
(−17 Da) and chlorine radical (−35 Da), respectively.
Furthermore the fragment ion at m/z 162 produced the
ion at m/z 127 by the loss of chlorine radical. The frag-
mentation of ion at mz/117 was attributed to the ion at
m/z 144 by the rearrangement of quinoline ring-opening
from six- to four-numbered ring, which was consistent
with the structure of (7-chloro-quinoline-4-yl) pipera-
zine. Thus, the proposed structure of imp-4 could be 4-
amino-7-chloro-quinoline. The probable fragmentationpathways of imp-1, imp-2 and imp-4 were shown in
Figure 2.
The imp-3 (Figure 3) with the accurate [M +H]+ ion
at m/z 248.0954, produced the abundant ion at m/z 205
by ring-opening (−43 Da). Further fragmentation of the
ion at m/z 205 yielded ions at m/z 191 and 177 by the
rearrangement (Figure 3). According to the main frag-
ment ions at m/z 205, 191 and 177, it was inferred that
the probable structure of imp-3 could be (7- chloro-
quinoline-4-yl) piperazine. The imp-5 (Figure 3) with
the accurate [M +H]+ ion at m/z 306.1378, produced
the same fragmentation pattern as imp-3 with the abun-
dant ions at m/z 205, 191 and 164, which indicated that
the structure of the imp-5 also could contain (7-chloro-
quinoline-4-yl) piperazine. The presence of minor ion at
m/z 102, which was formed by piperazine ring-opening
(−204 Da), indicated that the probable structure of imp-5
could be 1-hydroxy-3-(7-chloro-4-quinolin-4-piperazinyl)
Figure 3 Probable fragmentation pathways of piperaquine and imp-3, 5, 11, 12.
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ion at m/z 409.0987, with the same main fragment ions as
imp-3 and imp-5 at m/z 205, 177 and 164, which sug-
gested that the structure of imp-12 could also contain
(7-chloro-quinoline-4-yl) piperazine. Considering the pub-
lished data and the synthetic route [17], the imp-12 could
be produced due to excess 4, 7-dichloro-quinoline. As a
consequence, the proposed structure of imp-12 was de-
duced as 1, 4-bis-(4, 7-dichloroquinoline) piperazine.
The imp-11 (Figure 3) had the same molecular weight
as piperaquine with the accurate protonated ion at m/z
535.2146. The main fragmentation pattern at m/z 288,
260 and 217, was identical to that of piperaquine. It
could be concluded that the chlorine atom was sub-
stituted on C-5 position of a quinoline ring of imp-11, in-
stead of C-7 position of a quinoline ring of piperaquine.
The imp-6 (Figure 4) with the accurate [M +H]+ ion
at m/z 551.2094, which was 16 Da higher than that of
piperaquine, showed the corresponding protonated for-
mula of C29H33Cl2N6O
+ by TOF-MS. The main frag-
ment ions at 304 and 288 were consistent with those of
piperaquine. Based on consideration of the formation of
fragment ions and the synthetic route of piperaquine, it
was inferred that the probable structure of imp-6 was
proposed as a piperaquine oxygenate with a chloro quin-
oline ring substitued by hydroxyl group or a piperazine
ring of nitrogen oxides. The imp-8 and imp-10 (Figure 4)had the same molecular weight and the same fragmenta-
tion as imp-6, which indicated these two impurities could
also be a piperaquine oxygenate. Considering the chroma-
tographic retentions and the hydrophobic characters of
three impurities, the probable structures of imp-6, imp-8
and imp-10 were piperaquine oxygenates with a pipera-
zine ring of nitrogen oxides, C-8 and C-5 positions of a
chloro quinoline ring substituted by hydroxyl groups, re-
spectively, which was further confirmed by NMR data
(Table 1).
The imp-7 (Figure 4) with the accurate protonated ion
at m/z 585.2160, which was 50 Da higher than that of
piperaquine, indicated that piperaquine was replaced by
three hydroxyl groups with a piperazine ring opening.
According to the main fragment ions at m/z 374 and
288, and the synthetic route of piperaquine, it was inferred
that the structure of imp-7 could also be a piperaquine
oxygenate. The probable fragmentation pathways of imp-7
were shown in Figure 4.
For the imp-9 (Figure 4), the accurate [M +H]+ ion at
m/z 501.2536 was 34 Da less than that of piperaquine,
suggested a chloro quinoline ring of piperaquine could
lose a chlorine atom. A most abundant ion at m/z 288
was also observed in the MS2 spectrum of piperaquine.
The other main fragment ions at m/z 254, 266 and 211
were consistent with those of piperaquine without a chlor-
ine atom. Thus, the probable structure of the imp-9 could
Figure 4 Probable fragmentation pathways of imp-6, 7, 8, 9 and 10.
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Figure 5 Structural information of the piperaquine phosphate related impurities.
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Table 1 1H NMR data of related impurity 6 of piperaquine
phosphate
Positiona Number of protons Proton chemical shift, δH J
b (/Hz)
1, 1′ - - -
2, 2′ 2 8.88 8.45, d
3, 3′ 2 7.48 6.35, d
4, 4′ - - -
5, 5′ 2 8.20 8.33, d
6, 6′ 2 7.77 9.0, d
7, 7′ - - -
8, 8′ 2 8.27 6.36, d
9, 9′ - - -
10, 10′ - - -
11 - - -
12 4 4.35 ~ 4.37 m
13 4 4.26 ~ 4.28 m
14 - - -
15 2 3.71 br
16 2 2.73 br
17 2 3.46 br
18 - - -
19 4 4.07 ~ 4.12 m
20 4 4.16 ~ 4.21 m
aRefer the structural formula in Figure 6 for numbering.
b1H-1H coupling constants.




b/Hz) δC δH (J
b/Hz) δC
1 - - - -
2 7.95 (1H, d, 7.4) 139.9 8.45 (2H, d, 7.1) 144.5
3 6.10 (1H, d, 7.4) 109.2 7.09 (2H, d, 7.2) 107.2
4 11.91 (1H, s) 176.2 - 164.2
5 8.11 (1H, d, 8.7) 127.2 8.33 (2H, d, 9.3) 131.4
6 7.33 (1H, d, 10) 123.4 7.71 (2H, d, 7.8) 131.0
7 - 136.2 - 121.7
8 7.63 (1H, s) 117.4 8.07 (2H, d, 1.7) 122.8
9 - 140.8 - 143.4
10 - 124.3 - 120.4
11 - - - -
12 - - 4.48 (8H, s) 52.9
aRefer the structural formula in Figure 6 for numbering.
b1H-1H coupling constants.
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4-piperazinyl) propane. The ESI-MS and TOF-MS data
and probable fragmentation pathways of related impur-
ities in piperaquine bulk drug are shown in Figures 2, 3,
4 and 5.
Structure confirmation of impurities by 1H and 13C NMR
The TOF-MS spectrum of imp-2 had the accurate [M+H]+
ion at m/z 180.0207, consistent with the molecular for-
mula of C9H6ClNO. In the solution of DMSO-d6 and
TFA-d, the 1H-NMR data showed six hydrogen signals
with the area ratio of 1:1:1:1:1:1. By the experiment of
D2O exchange, the chemical shift of active hydrogen had a
downfield shift from 11.9 ppm to 3.5 ppm, and other five
hydrogen atoms were located at aromatic heterocyclic
rings. The 13C NMR and DEPT spectrum showed the
presence of nine carbon signals including four quaternary
carbons and five tertiary carbons. The 1H-NMR spectrum
showed that the presence of quinoline ring signals [δH
7.95 (1H, d, J = 7.4 Hz, H-2), δH 6.10 (1H, d, J = 7.4 Hz, H-
3), δH 11.91 (1H, s, H-4), δH 8.11 (1H, d, J = 8.7 Hz, H-5),
δH 7.33 (1H, d, J = 10 Hz, H-6) and δH 7.63 (1H, s, H-8)].
With the aid of 1H-1H COSY, HMQC and HMBC spec-
trums, all the 1H and 13C NMR data of imp-2 were listedin Table 2. The 13C NMR and HMBC spectrums showed
the presence of four quaternary carbon atoms [δC 176.2
(C-4), δC 136.2 (C-7), δC 140.8 (C-9) and δC 124.3 (C-10),
δH 6.10 (1H, d, J = 7.4 Hz, H-3) and δH 11.91 (1 H, s, H-4).
Hence, the chemical structure of imp-2 was verified as
shown in Figure 6.
The TOF-MS and ESI-MS analysis of imp-6 provided
a molecular formula of C29H32Cl2N6O ([M +H]
+, m/z
551.2094). The 1H-NMR and 1H-1H COSY spectrums
showed that the presence of quinoline ring signals [δH
8.27 (2H, d, J =25.8 Hz, H-8, 8′), δH 8.88 (2H, d, J =
6.35 Hz, H-2, 2′), δH 7.77 (2H, d, J = 9 Hz, H-6, 6′) and
δH 7.48 (2H, d, J = 6.4 Hz, H-3, 3′). The presence of
eight methylene group signals [δH 4.34 ~ 4.37 (4H, m,
H-12), δH 4.26 ~ 4.28 (4H, m, H13), δH 4.07 ~ 4.12 (4H,
m, H-19) and δH 4.16 ~ 4.21 (4H, m, H-20)], indicated
that these methylene groups were located at two pipera-
zine rings. Furthermore, three methylene group signals
[δH 3.71 (2H, br, H-15), δH 2.73 (2H, br, H-16) and δH
3.46 (2H, br, H-17)] were observed, with significant cor-
relation in the 1H-1H COSY spectrum, and H-15 had an
downfield shift due to oxidation at C-14. Thus, imp-6
was characterized as shown in Figure 6.
As to imp-12, ESI-MS and TOF-MS data showed the
accurate protonated ion at m/z 409.0987, with a molecu-
lar formula of C22H18Cl2N4. The
1H and 13C NMR data
of imp-12 were in agreement with the literature data
[17], thus the structure of imp-12 was confirmed as 1,
4-bis-(4, 7-dichoroquinoline) piperazine (Figure 6).
All 1H and 13C NMR signals of imp-2, 6 and 12 were
assigned in Tables 1 and 2, and all the structure deduc-
tions were also confirmed by ESI-MS and TOF-MS.
Figure 6 NMR assignments of (A) imp-2, (B) imp-6 and (C) imp-12.
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In the HPLC-UV/DAD, ESI-MS and TOF-MS experi-
ments, twelve related impurities were detected in pipera-
quine phosphate bulk drug. The starting material for
piperaquine phosphate, i.e. 4, 7-dichloro-quinoline, was
confirmed by the literature [17], and the imp-1, 2, 4
were the isomers of 4, 7-dichloro-quinoline bulk. Ac-
cording to the synthetic route, the imp-3, 5, 11, 12 were
the by-product in the synthetic reaction of piperaquine
phosphate. Based on the experiment of forced degrad-
ation samples, the imp-6–8, 10 were the oxidation
products and the imp-9 was the degradation product of
piperaquine phosphate. The possible mechanism of for-
mation of impurities was depicted in Figure 5.In silico toxicological predictions of impurities
To evaluate general toxicological and carcinogenic alerts
for the related impurities of piperaquine in silico, Toxtree®
and Derek®, the knowledge-based expert systems, were
used from different two (Q)SAR programs. Since the
imp-2, 6, 12 were the main related impurities in pipera-
quine bulk, the toxicity profiles of three impurities were
of paramount importance. By the module of the Cramerrules with extensions in Toxtree®, the imp-2, 6, 12 were
predicted to general toxicity risks (class III). Based on
Benigni/Bossa rulebase for mutagenicity and carcinogen-
icity, three related impurities were predicted negative for
carcinogenicity (genotox and nogenotox) and mutagenic-
ity. The predicted results of the module of structure alerts
for the in vivo micronucleus assay in rodents, showed that
the imp-6 and 12 were all H-acceptor-path3-H-acceptors
except the imp-2. Derek® predicted several toxicity alerts
for the imp 2, 6, 12: carcinogenicity in mammal (imp-2),
hERG channel inhibition (imp-6 and 12), hepatotoxicity
(imp-6 and 12), mutagenicity (imp-2) and alpha-2-mu-
Globulin nephropathy (imp-12).
The other piperaquine related impurities were also
predicted by Toxtree® to have a high general toxicity
risks similar with the imp-2, 6, 12 (class III). Further-
more, the imp-1, 3, 5 and 7–11 were predicted negative
for carcinogenicity (genotox and nogenotox) and muta-
genicity, while the imp-4 structure of primary aromatic
amine led to structural alert for genotoxic carcinogen-
icity. From the module of structure alerts for the in vivo
micronucleus assay in rodents, the imp-5 and 7–11 were
also H-acceptor-path3-H-acceptors, due to the similar
structures with the imp-6 and 12. The prediction results
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ities, such as carcinogenicity for the imp-8, hERG channel
inhibition for the imp-3–6 and imp-8–11, hepatotoxicity
for the imp-4, 6, 7, 9–11, skin sensitization for the imp-1,
8 and alpha-2-mu-Globulin nephropathy for the imp-4,
7–11. Only the imp-3 showed a non-toxic prediction
compared to other impurities.
According to the toxicological concern, the daily dos-
age of compounds classified in class III should be below
90 μg/person (60 kg)/day to be validated as non toxic
[18]. Therefore, the toxicity predicts of imp-1–12 pro-
vide valuable data for clinical use of piperaquine dose. In
China, the use of the piperaquine preparations is cau-
tioned for pregnant women and patients with severe
acute liver, kidney and heart diseases.
Conclusions
Twelve impurities of piperaquine phosphate bulk drug
were detected by HPLC-UV/DAD, ESI-MS and TOF-MS.
The structures of impurities were proposed on the basis of
ESI-MS and TOF-MS, fragmentation mechanism and syn-
thetic procedure. The imp-2, 6 and 12, three main related
impurities, were synthesized or isolated from the oxidation
samples of piperaquine phosphate by column chromatog-
raphy and these structures were confirmed by NMR
spectrum. Starting material along with impurities, syn-
thetic by-products, oxidation and degradation were the
main sources for the formation of these impurities. The
in-silico toxicological investigation (Toxtree® and Derek®)
indicated three main related impurities (imp-2, 6 and 12)
had general toxicity risks and nogenotox, which provided
the useful data in the research of piperaquine.
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